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Aims Pericardial effusion (PE) is a common finding in cardiac patients with chronic heart failure. The prognostic relevance
of a small, haemodynamically non-compromising PE in such patients, however, remains to be determined.
Methods
and results
All patients referred to our heart failure clinic and having a baseline echocardiography and follow-up clinical visits
were included. Patients with a haemodynamically relevant PE, acute myo-/pericarditis, systemic sclerosis, rheumatoid
arthritis, heart transplantation, heart surgery within the last 6 months or malignancies within the last 3 years were
excluded. Patients with or without a haemodynamically irrelevant PE were compared regarding all-cause mortality
as the primary and cardiovascular death or need for heart transplantation as secondary outcomes. A total of 897
patients (824 patients in the control vs. 73 patients in the PE group) were included. In the PE group, left ventricular
ejection fraction (LVEF) was lower [31%, interquartile range (IQR): 18.0–45.0] than in controls (34%, IQR: 25.0–47.0;
P ¼ 0.04), while the end-systolic diameters of the left ventricle and the left atrium were larger (P ¼ 0.01 and
P ¼ 0.001, respectively). Similarly, in patients with PE, the right ventricle (RV) systolic function was lower
(P, 0.005 for both the fractional area change and the tricuspid annulus movement), the dimensions of RV and
right atrium (RA) were larger (P, 0.05 for RV and P, 0.01 for RA), and the degree of tricuspid regurgitation
was higher (P, 0.0001). Furthermore, in the PE group, the heart rate was higher (P, 0.001) and the leukocyte
count as well as CRP values were increased (P ¼ 0.004 and P, 0.0001, respectively); beta-blocker use was less fre-
quent (P ¼ 0.04), while spironolactone use was more frequent (P ¼ 0.03). The overall survival was reduced in the PE
group compared with controls (P ¼ 0.02). Patients with PE were more likely to suffer cardiovascular death (1-year
estimated event-free survival: 86+5 vs. 95+1%; P ¼ 0.01) and to require heart transplantation (1-year estimated
event-free survival: 88+4 vs. 95+ 1%; P ¼ 0.009). A multivariate Cox proportional hazard model revealed the fol-
lowing independent predictors of mortality: (a) PE (P ¼ 0.04, hazard ratio (HR): 1.95, 95% confidence interval (CI):
1.0–3.7), (b) age (P ¼ 0.04, HR: 1.02, 95% CI: 1.0–1.04) and (c) LVEF ,35% (P ¼ 0.03, HR: 1.7, 95% CI: 1.1–2.8).
Conclusion In chronic heart failure, even minor PEs are associated with an increased risk of all-cause mortality, cardiac death, and
need for transplantation.
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Introduction
In patients with chronic heart failure, haemodynamically irrelevant
PE is a common (12–20%) finding during routine echocardiog-
raphy examinations.1– 3 Usually, such findings do not influence clin-
ical decision-making as long as the PE is not considered
haemodynamically compromising. While in some patients, pericar-
dial fluid accumulation can be attributed to an underlying systemic
or local inflammatory process4 such as cancer5 or myo-/pericardi-
tis6 or might occur after surgery,7 the mechanism of PE and its
prognostic value in heart failure remain elusive. Importantly, in
patients with severe pulmonary hypertension, several studies
have revealed a strong association of a small PE with adverse
outcome.8,9 The mechanism of increased pericardial fluid produc-
tion is incompletely understood in that patient population.10
Thus, it was the aim of the present study to evaluate the prog-
nostic relevance of haemodynamically insignificant PE in a heart
failure population and to identify potential mechanisms for pericar-
dial fluid accumulation in these patients.
Methods
Patient population and baseline
characteristics
We searched our echo-laboratory and heart failure clinic database and
identified all the patients who had undergone a baseline echocardiog-
raphy from 1990 until 2010 and had a baseline and at least one follow-
up visit in our heart failure clinic. The exclusion criteria were heart or
lung transplantation before the baseline echocardiography, cardiac
surgery within 6 months prior to baseline, myocardial infarction or sus-
pected acute peri-/myocarditis within the last 3 months, rheumatoid
arthritis, systemic sclerosis, systemic lupus, patients receiving chemo-
therapy due to cancer within the last 6 months, or patients with
known metastatic cancer. Patients presenting with a haemodynamically
relevant PE at baseline echocardiography were excluded as well.
Data on age, gender, body mass index, underlying heart rhythm,
underlying heart disease (ischaemic vs. non-ischaemic), O2 uptake
during exercise, New York Heart Failure (NYHA) functional class,
ICD/cardiac resynchronization therapy (CRT) implantation, and medi-
cation were retrieved from database and patient records.
Study groups and outcome measures
Patients presenting with a haemodynamically irrelevant PE on echocar-
diography were allocated to the PE group and the date of this echocar-
diogram represented the baseline. Patients with no signs of PE were
included in the control group and the first available echocardiography
represented the baseline. The primary outcome measure was all-cause
mortality. Secondary outcome measures were cardiovascular mortality
and need for heart transplantation. Inflammatory markers (leukocyte
count and C reactive protein) and the right ventricular function
were evaluated as well.
Echocardiography
All echocardiograms were analysed by two experienced physicians.
Echocardiographic parameters (grading of mitral and tricuspid regurgi-
tation, tricuspid annulus movement (TAM), left ventricular ejection
fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left
ventricular end-systolic diameter (LVESD), atrial and right ventricular
dimensions) were analysed according to current guidelines of the
European Society of Cardiology.11– 15 A PE was considered haemo-
dynamically relevant if at least one of the following criteria was
present: (i) paradoxical movement of the interventricular septum
with respiration, (ii) presence of a collapsing right ventricle during dia-
stole, and (iii) typical ventricular E-wave velocity changes with
inspiration.16
Haemodynamic parameters
Patients with a PE who underwent left and right heart catheterization
at baseline were matched to patients in the control group with data
available on left and right heart catheterization. Patients were
matched 1:1 with regard to age, gender, NYHA functional class, ischae-
mic vs. non-ischaemic cardiomyopathy, diuretic, angiotensin converting
enzyme (ACE) inhibitor and beta-blocker treatment, and LVEF.
The left ventricular end-diastolic pressure, right ventricular end-
diastolic pressure, wedge pressure as well as the mean pulmonary
arterial pressure were investigated. The transpulmonary gradient was
calculated as mean pulmonary artery pressure2 mean wedge
pressure.
Laboratory parameters
Blood samples were taken at baseline. The leucocyte count was
recorded. C-reactive protein and NT-proBNP levels were analysed
using the cobasw analyzer (Roche Diagnostics, Basel, Switzerland) at
the Institute of Clinical Chemistry of the University Hospital Zurich.
Follow-up examination
All patients had at least one follow-up visit in the heart failure clinic.
Usually, patients were examined every 6 months by a heart failure spe-
cialist with a physical examination, and laboratory analysis including
blood count, CRP, proBNP, and creatinine. Patients with a recently
detected cancer were identified. If a patient died during follow-up,
the results of an autopsy or the latest medical reports were analysed
to identify the cause of death.
In patients with PE at baseline, all follow-up echocardiograms were
analysed to document the evolution of the PE, and the time to reso-
lution of the PE from a baseline was determined. In patients with PE
at baseline, chest X-rays at baseline were examined for concomitant
pleural effusions and noted as uni- or bilateral.
Statistics
All statistical analyses were performed using SPSS 20.0 (IBM Corpor-
ation, 1 New Orchard Road Armonk, New York 10504-1722, USA).
Continuous variables are presented as the median and interquartile
range (IQR) (25–75 percentile). The x2 and Mann–Whitney U test
were used as appropriate. For survival analysis, a Kaplan–Meier
curve was computed and a log rank P-value was calculated. A Cox pro-
portional hazard model was applied for the primary outcome measure,
corrected for age, gender, heart rate, heart rhythm, LVEF ,35%, body
mass index, underlying heart disease, beta-blocker, and spironolactone
therapy.
A sensitivity analysis with a Cox proportional hazard model was per-
formed for mortality, also adjusting for NT-proBNP and CRP values
(NT-proBNP and CRP were both obtained in 181 patients only).
A two-sided P-value of ,0.05 was considered significant.
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Results
Patient population and baseline
characteristics
A total of 1213 patients were retrieved from the database. One
hundred patients having undergone heart or lung transplantation
before the baseline echocardiography as well as 147 patients
after recent cardiac surgery were excluded. Furthermore, 49
patients having sustained a myocardial infarction within 3 months
before the baseline echocardiography, 6 patients with acute
peri-/myocarditis, and 11 patients with uncontrolled cancer were
also excluded. Three patients had a haemodynamically significant
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Table 1 Baseline characteristics
No pericardial effusion (n5 824) Pericardial effusion (n 5 73) P-value
Age (years) 55.5 (45.9–64.5) 53.4 (34.4–62.7) 0.05
Male (n, %) 675 (82) 53 (73) 0.06
BMI (kg/m2) 25.8 (23.4–29.2) 24.7 (21.1–27.0) 0.004
Heart rate (b.p.m.) 76.0 (65.0–89.0) 87.0 (76.0–98.0) ,0.0001
VO2max (ml/kg/min) 19.0 (15.0–25.0) 15.0 (13.0–21.5) 0.15
Rhythm (n, %) 0.03
Sinus rhythm 601 (81) 41 (66)
Atrial fibrillation 95 (13) 14 (23)
Pacemaker 46 (6) 7 (11)
NYHA class (n, %) 0.01
I 49 (9) 2 (4)
II 239 (42) 12 (24)
III 241 (43) 29 (57)
IV 37 (7) 8 (16)
Cardiomyopathy (n, %)
Dilatative/hypertrophic 311 (38) 45 (62)
Non-compaction 16 (2) 0
Dilatative cardiomyopathy/history of myocarditis 0 2 (3)
Amyloid 2 (0) 0
Ischaemic 287 (35) 14 (19)
Valvular 53 (6) 4 (6)
Congenital 32 (4) 2 (3)
Other/unknown 123 (15) 6 (8)
Leucocyte count (103/mL) 7.7 (6.1–9.1) 8.4 (7.0–11.3) 0.004
C-reactive protein (mg/L) 3.0 (1.0–12.0) 15.0 (4.2–40.3) ,0.0001
Platelets (103/mL) 223 (185–272) 223 (182–293) 0.47
NT-proBNP (ng/L) 1214 (411–2596) 2240 (1085–5379) 0.01
Sodium (mmol/L) 140 (137–141) 139 (137–141) 0.27
Haemoglobin (g/dL) 13.8 (12.8–14.9) 13.1 (11.5–14.7) 0.008
Creatinine (mmol/L) 103 (89–124) 101 (86.8–121) 0.68
Diuretics (n, %) 543 (66) 52 (71) 0.44
Calciumantagonist (n, %) 58 (7) 10 (14) 0.06
Digoxin (n, %) 165 (20) 15 (21) 0.88
ACE inhibitor (n, %) 447 (54) 43 (59) 0.46
ATII blocker (n, %) 88 (11) 7 (10) 0.77
Spironolactone (n, %) 100 (12) 16 (22) 0.03
Statin (n, %) 159 (19) 10 (14) 0.28
Beta-blocker (n, %) 479 (58) 33 (45) 0.04
ICD (n, %) 53 (6) 6 (8) 0.47
CRT (n, %) 28 (3) 2 (3) 0.76
Inclusion before 2001 (n, %) 306 (37) 22 (30) 0.26
Continuous variables are presented as median and interquartile range in brackets and nominal variables are presented as number and percentage in brackets.
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PE. Among the 897 patients finally included, 73 patients exhibited a
haemodynamically irrelevant PE.
There was a borderline significant difference between the PE
and the control group with regard to age [53.4 years (IQR:
34.4–62.7) vs. 55.5 years (IQR: 45.9–64.5); P ¼ 0.05], but not
with regard to male gender (53 patients (73%) vs. 675 patients
(82%), P ¼ 0.06). A body mass index was lower in the PE group
[24.7 kg/m2 (IQR: 21.1–27.0) vs. 25.8 kg/m2 (IQR: 23.4–29.2),
P ¼ 0.004; Table 1].
The heart rate was higher in patients with PE (87/min, IQR: 76.0–
98.0) than that in controls (76/min, IQR: 65.0–89.0, P, 0.0001), use
of beta-blockers was lower in patients with PE (33 patients, 45%) than
in controls (479 patients, 58%, P ¼ 0.04) and the number of patients
with non-ischaemic cardiomyopathy was higher in the PE group
(n ¼ 57, 78%) than in controls (n ¼ 502, 61%).
Thirty-one (43%) patients with PE had a chest X-ray at baseline.
In 20 (64%) patients, a concomitant pleural effusion was found and
in most cases located bilaterally (n ¼ 11; 55%).
Left ventricular and atrial parameters
The left ventricular ejection fraction was lower (31% (IQR: 18.0–
45.0) vs. 34% (IQR: 25.0–47.0); P ¼ 0.04) and LVESD was larger in
the PE (5.6 cm, IQR: 4.0–6.7) than the control group (4.9 cm, IQR:
3.7–5.9; P ¼ 0.01). The left atrial endsystolic diameter was larger in
the PE (5.0 cm, IQR: 4.4–5.8) than the control group (4.6 cm, 4.0–
5.2); P ¼ 0.001). The severity of mitral regurgitation did not differ
between the PE and the control group [Grade 2 (IQR: 1–3) vs.
Grade 2 (IQR: 1–2); P ¼ 0.67, Table 2].
Right ventricular and atrial parameters
The right ventricular diameter (four-chamber view, short axis) was
increased [3.5 cm (IQR: 2.9–4.0) vs. 3.2 cm (IQR: 2.7–3.6); P ¼
0.02] and the right ventricular systolic function was decreased in
patients with PE compared with the control group: RV-fac
[median 33% (IQR: 19.0–42.0) vs. 39% (IQR: 33.0–49.0); P ¼
0.002], tricuspid annulus movement [median 14.5 mm (IQR:
11.8–20.0) vs. 18.0 mm (IQR: 15.0–21.0); P ¼ 0.003; Figure 1].
The right atrial end-systolic diameter was larger in the PE than
the control group (P ¼ 0.001). Tricuspid regurgitation was more
pronounced in the PE than the control group [Grade 2 (IQR: 1–2)
vs. Grade 1 (IQR: 1–2); P, 0.0001; Table 2].
Haemodynamic parameters
In the patient population with PE, 29 patients (40%) had left and
right heart catheterization at baseline. These patients were
matched 1:1 to patients retrieved from the control group. No sig-
nificant difference between the groups was detected with regard
to age, gender, NYHA functional class, diuretic or ACE inhibitor
or beta-blocker treatment, ischaemic vs. non-ischaemic cardiomy-
opathy, and LVEF.
Patients with PE had a higher right ventricular end-diastolic pres-
sure [8.5 mmHg (IQR: 6.0–15.5) vs. 6.5 mmHg (IQR: 3.0–10.0);
P ¼ 0.008] and mean pulmonary arterial pressure [32.0 mmHg
(IQR: 22.5–43). vs. 22.5 mmHg (IQR: 16.3–36); P ¼ 0.03],
whereas the left ventricular end-diastolic pressure [22.5 mmHg
(IQR: 18.3–30.8) vs. 20 mmHg (IQR: 13.3–26.3); P ¼ 0.27] and
the wedge pressure [20 mmHg (IQR: 14.0–27.0) vs. 16 mmHg
(IQR: 9.5–24.5); P ¼ 0.14] did not differ between the study
groups (Figure 2). The transpulmonary gradient was higher in the
PE group 12.0 mmHg, IQR: 6.5–18.5; P ¼ 0.04) compared with
controls (7.0 mmHg, IQR: 4.0–12.0).
Laboratory markers of cardiac function
and inflammation
NT-proBNP, CRP, and leukocyte values at baseline were available
in 232, 344, and 589 patients, respectively. The NT-proBNP value
was significantly increased in the PE group compared with controls
[2240 ng/L (IQR: 1085–5379) vs. 1214 ng/L (IQR: 411–2596);
P ¼ 0.01].
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Table 2 Echocardiography baseline parameters
No pericardial
effusion
(n5 824)
Pericardial
effusion
(n5 73)
P-value
LVEF 34.0 (25.0–47.0) 31.0 (18.0–45.0) 0.04
LVESD 4.9 (3.7–5.9) 5.6 (4.0–6.7) 0.01
LVEDD 6.2 (5.3–7.0) 6.4 (5.4–7.4) 0.16
Mitral regurgitation 0.59
Minor 200 (32) 15 (25)
Moderate 296 (48) 28 (47)
Severe 79 (13) 10 (18)
Tricuspid regurgitation ,0.0001
Minor 347 (57) 19 (31)
Moderate 202 (34) 27 (44)
Severe 31 (5) 12 (19)
Fac (%) 39.0 (33.0–49.0) 33.0 (19.0–42.0) 0.002
TAM (mm) 18.0 (15.0–21.0) 14.5 (11.8–20.0) 0.003
Right
ventricular
diameter
(cm)
3.2 (2.7–3.6) 3.5 (2.9–4.0) 0.02
Right
ventricular
end-diastolic
area (cm2)
18.0 (14.7–22.0) 21.9 (16.0–28.0) 0.001
Right atrial
diameter
long axis
(cm)
5.2 (4.7–5.9) 5.9 (4.9–6.5) 0.005
Right atrial
diameter
short axis
(cm)
4.1 (3.6–4.6) 4.5 (3.9–5.5) 0.001
Left atrial
endsystolic
diameter
(cm)
4.6 (4.0–5.2) 5.0 (4.4–5.8) 0.001
Pulmonary
pressure
elevated
199 (24) 33 (45) 0.03
Continuous variables are presented as median and interquartile range in brackets
and nominal variables are presented as number and percentage in brackets.
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Laboratory markers of inflammation were significantly increased
in the PE group compared with controls, i.e. the leucocyte count
was higher [8.4 × 103/mL (IQR: 7.0–11.3) vs. 7.7 × 103/mL (IQR:
6.1–9.1); P ¼ 0.004] as were the plasma levels of C-reactive
protein [15.0 mg/L (IQR: 4.2–40.3) vs. 3.0 mg/L (IQR: 1.0–12.0);
P, 0.0001); Figure 3].
A Cox proportional hazard model (analysing n ¼ 181 patients)
confirmed an independent association of PE (p ¼ 0.03; HR 3.2,
95% CI 1.1–9.4) and NT-proBNP (per 100 ng/L: P, 0.0001,
hazard ratio (HR): 1.01, 95% CI: 1.007–1.02), but not CRP (per
mg/L: P ¼ 0.47, HR: 1.005, 95% CI: 0.99–1.02) with mortality.
Echocardiographic follow-up
Fifty-three (73%) patients in the PE group had an echocardiograph-
ic follow-up. The median follow-up period was 4.4 months (IQR:
1.8–14). Thirteen (25%) patients had persisting PE. Four patients
(31%) with persisting PE died, while only 6 patients (15%) died
in the group with resolved PE (1-year estimated event-free survival:
63.5+15% vs. 96.7+ 3%; P ¼ 0.007).
Clinical follow-up
The median follow-up time was 1.8 years (IQR: 0.3–5.5) in the PE
group and 3.4 years (IQR: 1.1–7.1) in the control group. A total of
209 patients (23%) died with 159 patients (18%) dying from a
cardiac cause, 11 patients (1%) from infection, and 14 patients
(2%) from cancer. In 15 patients (2%) the cause of death remained
unknown (Table 3). In 38 patients (4%) a malignancy was diagnosed
during the follow-up period.
The overall survival was significantly reduced in patients with PE
as compared with controls (Figure 4; P-value ¼ 0.02). A Cox propor-
tional hazard model revealed an independent association of PE with
death (Table 4; P ¼ 0.04). Patients in the PE group were more likely
to die from a cardiac cause as compared with the control group
(1-year estimated event-free survival: 86+5 vs. 95+1%; P ¼
0.01; Table 3). Heart transplantation was necessary in 77 (9%)
patients. Patients with a PE were more likely to require transplant-
ation when compared with the control group (1-year estimated
event-free survival: 88+4% vs. 95+1%; P ¼ 0.009; Table 3).
Discussion
This study demonstrates that in a chronic heart failure population
the presence of a haemodynamically irrelevant PE is independently
associated with a nearly two-fold hazard of death. Of note, a per-
sistent PE at echocardiographic follow-up was associated with un-
favourable outcome when compared with patients with resolved
Figure 1 Parameters of the right ventricular function and dimension.
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PE. Cardiovascular events were the main cause of death in these
patients with as well as in those without PE; however, at 1 year,
patients with PE had an increased risk to die from a cardiac
cause compared with those without it, and they were more
likely to require heart transplantation. In addition, patients with
PE had a higher NT-proBNP level identifying a higher risk popula-
tion for major adverse events.17,18 Consistent with these observa-
tions, patients with PE had a lower left and right ventricular
ejection fraction, larger left and right atrial dimensions, and a
worse NYHA functional class.
While the exact underlying mechanisms, by which the PE might
be associated with adverse outcome remains to be deter-
mined,19,20 the results of the present study suggest that congestion
of venous blood or lymphatic fluid return to the right heart might
have an impact on the evolution of PE of non-inflammatory origin.
Furthermore, pulmonary pressure per se and/or regulatory
mechanisms operative under these conditions seem to be of im-
portance. Nevertheless, the mechanisms by which PE might be
associated with adverse outcome remain speculative. In patients
with severe pulmonary hypertension, an impaired right ventricular
function and/or a PE are detected in 22 and 25%, respectively, and
both are independently associated with a poor prognosis.21
Intriguingly, it has been shown previously that NT-proBNP reflects
the right ventricular structure and function in patients with pul-
monary hypertension.22 In line with this interpretation, in the
present study, patients with a PE exhibited a worse right ventricu-
lar function, larger right ventricular and right atrial dimensions,
more pronounced tricuspid regurgitation as well as a higher preva-
lence of pulmonary hypertension and elevated NT-proBNP, when
compared with controls. In the subgroup of patients with left and
right heart catheterization at baseline, patients with PE did indeed
exhibit significantly elevated right ventricular filling pressures and
an increased mean arterial pulmonary pressure, whereas the left
ventricular filling pressure and wedge pressure did not differ
between the PE and the control group. These data provide
evidence for an important role of the right ventricular function in
the development of PE in heart failure patients. The transpulmonary
gradient was increased in the PE group suggesting that a reactive
component on top of the left ventricular dysfunction might contrib-
ute to pulmonary hypertension.23
The right ventricular and haemodynamic data support and extend
the findings of a recent study identifying the right ventricular func-
tion, right ventricular dimension, and pulmonary hypertension as
major determinants of functional tricuspid regurgitation,24 but
Figure 2 Left and right ventricular filling pressures at baseline.
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further demonstrate an association of such changes with PE. Similar
data were demonstrated in patients with predominantly preserved
LVEF.25 However, the latter study was limited by the inclusion of
all patients with PE; moreover, detailed echocardiographic data on
right ventricular function and haemodynamics were not presented.
In contrast, a recently published study failed to show a prognostic
Figure 3 Inflammatory parameters and NT-proBNP.
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Table 3 Follow-up in the study groups
No pericardial effusion
(n 5 824)
Pericardial effusion
(n5 73)
P-value
Follow-up (years) 3.4 (1.1–7.1) 1.8 (0.3–5.5) 0.03
Death 186 (23) 23 (32)
Cardiac death 142 (17) 17 (23)
Infection 10 (1) 1 (1)
Unknown 13 (2) 2 (3)
Cancer 12 (2) 2 (3)
Other 9 (1) 1 (1)
Cancer 33 (4) 5 (7)
Cardiac death: 1-year estimator of event-free survival 95+1 86+5 0.01
Heart transplantation 66 (8) 11 (15)
Heart transplantation: 1-year estimator of event-free survival 95+1 88+4 0.009
Continuous variables are presented as median and interquartile range in brackets and nominal variables are presented as number and percentage in brackets.
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impact of PE in patients with chronic heart failure.26 Unfortunately,
only half of the baseline population could finally be included in that
study. Moreover, the selection of the patients enrolled remained
unclear, and may explain that in a multivariate analysis PE was not
an independent predictor of mortality. Consistent with the findings
of our study, however, the same authors demonstrated that right
atrial and right ventricular diameters were increased, ejection frac-
tion was lower, and mortality was higher in the PE group.
In a subgroup analysis, patients with a resolved PE had a more
favourable outcome compared with patients with persisting PE in-
dicating improved heart failure treatment and recompensation in
patients with resolved PE. In contrast, a persistent PE caused by
the chronic volume overload may identify a patient population at
particularly increased risk.
Numerous systemic or local inflammatory conditions such
as rheumatoid diseases,27 myo-/pericarditis,6 or cancer28 may
increase permeability and in turn lead to a capillary leak and the
development of a PE.29 Of note, severe heart failure goes along
with systemic inflammation as well.30,31 In the present study, leuko-
cyte counts and C-reactive protein levels were increased in
patients with PE when compared with those without it, suggesting,
that the systemic inflammation occurring in severe heart failure
might induce some capillary leakage thereby contributing to
pericardial fluid accumulation. Since markers of inflammation are
associated with a worse outcome also in patients with chronic
heart failure,32 it cannot be excluded that the presence of PE
merely reflects the presence of such a systemic inflammatory
reaction in these patients. Noteworthy, in the present study,
64% of patients with PE had a concomitant pleural effusion at base-
line. It is well known that an elevation of the systemic venous pres-
sure and inflammation may affect both pericardial and pleural
effusions.10
Haemodynamically non-compromising PE carries a worse prog-
nosis especially in patients with heart failure and persistent PE
despite heart failure therapy according to current guidelines.33
Our findings therefore suggest the need for an intensified surveil-
lance of patients in whom PEs are detected. In how far an opti-
mized heart failure treatment with, e.g. implanted devices, to
improve fluid management will lead to a reduction in PE and an
Figure 4 Kaplan–Meier survival analysis of heart failure patients with pericardial effusion compared with those without (p ¼ 0.02).
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Table 4 Cox proportional hazard model
Variable Hazard
ratio
95%
confidence
intervals
P-value
Left ventricular ejection
fraction ,35%
1.70 1.1–2.8 0.03
Pericardial effusion 1.95 1.0–3.7 0.04
Age (per year) 1.02 1.0–1.04 0.04
Heart rate (per b.p.m.) 1.01 1.0–1.03 0.051
Male gender 0.67 0.37–1.2 0.14
Sinus rhythm vs. atrial
fibrillation
0.74 0.35–1.5 0.41
Ischaemic vs.
non-ischaemic
cardiomyopathy
0.77 0.49–1.2 0.24
Spironolactone
treatment
0.85 0.43–1.3 0.64
Beta-blocker treatment 0.84 0.54–1.3 0.43
Body mass index (kg/m2) 1.01 0.97–1.1 0.66
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improved outcome in these patients needs to be clarified in a pro-
spective randomized trial.
Limitations
Observational studies are prone to confounding bias and missing
values. Especially, biomarker data were available only in a small
subset of patients. We have performed multivariate adjustments
to reduce the confounding but we cannot be sure that there is
no residual confounding, especially with regard to variables
which were not included in the model. Moreover, in comparison
to the overall study population, the subgroup with PE is relatively
small which could limit the robustness of the results. A transient
appearance of a PE between the follow-up visits in some of the
patients cannot be excluded. We do report on a long recruitment
and observation period ranging from 1990 to 2010, but a similar
number of patients with PE was included before the year 2001
which renders major observational biases unlikely; therefore, a po-
tential change in medication and daily clinical practice has probably
not influenced the results obtained.
Conclusion
In summary, this study suggests that even haemodynamically irrele-
vant PEs, as detected by echocardiography, are associated with
adverse outcome. Potential (but speculative) mechanisms are
right ventricular failure and systemic inflammation due to severe
heart failure. In how far an optimized heart failure treatment
decreases pericardial fluid accumulation along with improving sur-
vival needs further consideration in a prospective trial.
Funding
G.M.F. is supported by a grant of the Swiss National Science Founda-
tion, Nr. PBZHP3_143671.
Conflict of interest: none declared.
References
1. Kataoka H. Pericardial and pleural effusions in decompensated chronic heart
failure. Am Heart J 2000;139:918–923.
2. Maisch B. Pericardial diseases, with a focus on etiology, pathogenesis, pathophysi-
ology, new diagnostic imaging methods, and treatment. Curr Opin Cardiol 1994;9:
379–388.
3. Kessler KM, Rodriguez D, Rahim A, Dheen M, Samet P. Echocardiographic obser-
vations regarding pericardial-effusions associated with cardiac disease. Chest 1980;
78:736–740.
4. Ben-Horin S, Portnoy O, Pauzner R, Livneh A. Localized pericardial inflammation
in systemic lupus erythematosus. Clin Exp Rheumatol 2004;22:483–484.
5. Wagner PL, McAleer E, Stillwell E, Bott M, Rusch VW, Schaffer W, Huang J.
Pericardial effusions in the cancer population: prognostic factors after pericardial
window and the impact of paradoxical hemodynamic instability. J Thorac Cardiovasc
Surg 2011;141:34–38.
6. Cooper LT Jr. Myocarditis. N Engl J Med 2009;360:1526–1538.
7. Ashikhmina EA, Schaff HV, Sinak LJ, Li Z, Dearani JA, Suri RM, Park SJ,
Orszulak TA, Sundt TM III. Pericardial effusion after cardiac surgery: risk
factors, patient profiles, and contemporary management. Ann Thorac Surg 2010;
89:112–118.
8. Launay D, Humbert M, Berezne A, Cottin V, Allanore Y, Couderc LJ, Bletry O,
Yaici A, Hatron PY, Mouthon L, Le Pavec J, Clerson P, Hachulla E. Clinical char-
acteristics and survival in systemic sclerosis-related pulmonary hypertension asso-
ciated with interstitial lung disease. Chest 2011;140:1016–1024.
9. Hinderliter AL, Willis PWt, Long W, Clarke WR, Ralph D, Caldwell EJ,
Williams W, Ettinger NA, Hill NS, Summer WR, de Biosblanc B, Koch G, Li S,
Clayton LM, Jobsis MM, Crow JW. Frequency and prognostic significance of
pericardial effusion in primary pulmonary hypertension. Pph study group.
Primary pulmonary hypertension. Am J Cardiol 1999;84:481–484, A410.
10. Natanzon A, Kronzon I. Pericardial and pleural effusions in congestive heart
failure-anatomical, pathophysiologic, and clinical considerations. Am J Med Sci
2009;338:211–216.
11. Elliott Perry, Andersson Bert, Arbustini Eloisa, Bilinska Zofia, Cecchi Franco,
Charron Philippe, Dubourg Olivier, Ku¨hl Uwe, Maisch Bernhard,
McKenna William J, Monserrat Lorenzo, Pankuweit Sabine, Rapezzi Claudio,
Seferovic Petar, Tavazzi Luigi, Keren Andre. Classification of the cardiomyop-
athies: a position statement from the European society of cardiology working
group on myocardial and pericardial diseases. Eur Heart J 2008;29:270–276.
12. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K,
Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assess-
ment of the right heart in adults: a report from the American Society of Echocar-
diography endorsed by the European Association of Echocardiography, a
registered branch of the European Society of Cardiology, and the Canadian
Society of Echocardiography. J Am Soc Echocardiogr 2010;23:685–713; quiz
786–688.
13. Evangelista A, Flachskampf F, Lancellotti P, Badano L, Aguilar R, Monaghan M,
Zamorano J, Nihoyannopoulos P. European association of echocardiography
recommendations for standardization of performance, digital storage and report-
ing of echocardiographic studies. Eur J Echocardiogr 2008;9:438–448.
14. The Joint Task Force on the Management of Valvular Heart Disease of the Euro-
pean Society of Cardiology (ESC) and the European Association for Cardio-
Thoracic Surgery ACTS). Guidelines on the management of valvular heart
disease (version 2012) (Eur J Echocardiography (2006) 7, 79e108). Eur Heart J
2012;33:2451–2496.
15. Lang Roberto M, Bierig Michelle, Devereux Richard B, Flachskampf Frank A,
Foster Elyse, Pellikka Patricia A, Picard Michael H, Roman Mary J,
Seward James, Shanewise Jack, Solomon Scott, Spencer Kirk T, John
Sutton Martin St, Stewart William. Recommendations for chamber quantification.
Eur J Echocardiography 2006;7:79e108.
16. Appleton CP, Hatle LK, Popp RL. Cardiac tamponade and pericardial effusion: re-
spiratory variation in transvalvular flow velocities studied by Doppler echocardi-
ography. J Am Coll Cardiol 1988;11:1020–1030.
17. Luchner A, Mockel M, Spanuth E, Mocks J, Peetz D, Baum H, Spes C, Wrede CE,
Vollert J, Muller R, Katus H, Giannitsis E. N-terminal pro brain natriuretic peptide
in the management of patients in the medical emergency department (prompt):
correlation with disease severity, utilization of hospital resources, and prognosis
in a large, prospective, randomized multicentre trial. Eur J Heart Fail 2012;14:
259–267.
18. Bayes-Genis A, de Antonio M, Galan A, Sanz H, Urrutia A, Cabanes R, Cano L,
Gonzalez B, Diez C, Pascual T, Elosua R, Lupon J. Combined use of high-sensitivity
st2 and ntprobnp to improve the prediction of death in heart failure. Eur J Heart
Fail 2012;14:32–38.
19. Miller AJ, Pick R, Johnson PJ. The rates of formation of cardiac lymph and pericar-
dial fluid after the production of myocardial venous congestion in dogs. Lymphol-
ogy 1972;5:156–160.
20. Cui Y. The role of lymphatic vessels in the heart. Pathophysiology 2010;17:
307–314.
21. Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS,
Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD. Predicting sur-
vival in pulmonary arterial hypertension: insights from the registry to evaluate
early and long-term pulmonary arterial hypertension disease management
(reveal). Circulation 2010;122:164–172.
22. Gan CT, McCann GP, Marcus JT, van Wolferen SA, Twisk JW, Boonstra A,
Postmus PE, Vonk-Noordegraaf A. Nt-probnp reflects right ventricular structure
and function in pulmonary hypertension. Eur Respir J 2006;28:1190–1194.
23. Hoeper MM, Barbera JA, Channick RN, Hassoun PM, Lang IM, Manes A,
Martinez FJ, Naeije R, Olschewski H, Pepke-Zaba J, Redfield MM, Robbins IM,
Souza R, Torbicki A, McGoon M. Diagnosis, assessment, and treatment of non-
pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol
2009;54:S85–S96.
24. Topilsky Y, Khanna A, Le Tourneau T, Park S, Michelena H, Suri R, Mahoney DW,
Enriquez-Sarano M. Clinical context and mechanism of functional tricuspid regur-
gitation in patients with and without pulmonary hypertension. Circ Cardiovasc
Imaging 2012;5:314–323.
25. Mitiku TY, Heidenreich PA. A small pericardial effusion is a marker of increased
mortality. Am Heart J 2011;161:152–157.
26. Yu SB, Zhao QY, Huang H, Chen DE, Cui HY, Qin M, Huang CX. Prognosis
investigation in patients with chronic heart failure and pericardial effusion. Chin
Med J 2012;125:882–887.
27. Sugiura T, Kumon Y, Kataoka H, Matsumura Y, Takeuchi H, Doi Y. Asymptomatic
pericardial effusion in patients with rheumatoid arthritis. Cardiology 2008;110:
87–91.
G.M. Fro¨hlich et al.1422
28. Refaat MM, Katz WE. Neoplastic pericardial effusion. Clin Cardiol 2011;34:
593–598.
29. Airaghi L, Montori D, Santambrogio L, Miadonna A, Tedeschi A. Chronic systemic
capillary leak syndrome. Report of a case and review of the literature. J Intern Med
2000;247:731–735.
30. Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflam-
mation in heart failure—the whys and wherefores. Heart Fail Rev 2006;11:83–92.
31. Dixon DL, Griggs KM, Bersten AD, De Pasquale CG. Systemic inflammation and
cell activation reflects morbidity in chronic heart failure. Cytokine 2011;56:
593–599.
32. Guder G, Frantz S, Bauersachs J, Allolio B, Wanner C, Koller MT, Ertl G,
Angermann CE, Stork S. Reverse epidemiology in systolic and nonsystolic heart
failure: Cumulative prognostic benefit of classical cardiovascular risk factors.
Circ Heart Fail 2009;2:563–571.
33. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L,
Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S,
Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ. Guidelines for
the diagnosis and treatment of chronic heart failure: executive summary
(update 2005): the task force for the diagnosis and treatment of chronic heart
failure of the European Society of Cardiology. Eur Heart J 2005;26:1115–1140.
CARDIOVASCULAR FLASHLIGHT
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
doi:10.1093/eurheartj/eht038
Online publish-ahead-of-print 5 February 2013
Pre- and post-operative assessment of valvular and aortic flow using 4D
flow magnetic resonance imaging
Robert Manka1,2,3*, Julia Busch2, Gerard Crelier2, Thomas F. Lu¨scher1, and Sebastian Kozerke2
1Clinic of Cardiology, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland; 2Institute for Biomedical Engineering, University and ETH Zurich,
Gloriastrasse 35, CH-8092 Zurich, Switzerland; and 3Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Raemistrasse 100,
CH-8091 Zurich, Switzerland
* Corresponding author. Tel: +41 44 255 1251, Fax: +41 44 255 4506, Email: robert.manka@usz.ch
This paper was guest edited by Brahmajee Kartik Nallamothu, University of Michigan, Ann Arbor, MI, USA,
Email: bnallamo@umich.edu.
Findings in a 71-year-old male patient are reported who pre-
sented with an aneurysm of the ascending aorta and a heavily cal-
cified bicuspid aortic valve with severe stenosis and mild
regurgitation. Transthoracic echocardiography and invasive as-
sessment showed normal left ventricular function, a severely
reduced valve area of 0.77 cm2, and a dilation of the ascending
aorta of 52 mm. To further investigate the haemodynamic influ-
ence of the valvular and aortic pathology, a pre- and post-
operative assessment using time-resolved three-dimensional
phase-contrast magnetic resonance imaging (4D Flow MRI)
was performed using a 1.5T MR scanner (Philips Achieva, Best,
The Netherlands). Blood flow analysis was performed using a
prototype software package (GTFlow, GyroTools, Zurich, Switz-
erland). After the pre-operative 4D Flow MRI exam, the patient
underwent replacement of the aortic root with a biological
aortic valve prosthesis (25 mm, Medtronic Freestylew) and of
the ascending aorta, using a collagen-impregnated woven pros-
thesis (28 mm, Hemashield Wovenw). A post-operative 4D
Flow MRI scan was obtained 85 days after the operation.
Panels 1A and B compare pathlines pre- and post-operation.
While helical flow patterns are observed in the ascending
aorta pre-operation (Panel 1A, Supplementary material online, Movie S1), normal flow patterns are found after the operation (Panel
1B, Supplementary material online, Movie S2). The distinct systolic retrograde flow channel (Panels 1C and E) observed pre-operation
disappeared entirely after the operation (Panels 1D and F ), indicating increased efficiency of blood transport. Likewise, systolic peak
flow was significantly reduced after the operation (Panels 1E and F ). In summary, this example demonstrates the value of 4D Flow MRI
in assessing patients with valvular and aortic disease. The method holds potential for advanced pre-operative patient assessment and
follow-up monitoring with particular emphasis on quantifying haemodynamic implications of structural alterations in a non-invasive and
comprehensive manner.
Supplementary material is available at European Heart Journal online.
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